Clinical Trials Logo

Radiation Dermatitis clinical trials

View clinical trials related to Radiation Dermatitis.

Filter by:

NCT ID: NCT04149522 Terminated - Breast Cancer Clinical Trials

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this research is to evaluate the use of Mepitel Film® in preventing radiation epidermitis in patients receiving radiation treatment for breast cancer. Mepitel® Film is a thin, flexible, waterproof, and breathable film made of a soft silicone layer and polyurethane film. Mepitel ® film is not made with natural rubber latex (NRL). It is FDA approved for the management of superficial wounds, such as superficial burns. As a part of this research study, the Mepitel Film® will be placed prior to participant's first radiation treatment, and will be removed one week following the end of treatment. Throughout the study, information will be collected to analyze at the end of the research study to determine if the Mepitel Film® helps prevent skin breakdown. The subjects will be followed per standard of care and examined for skin redness, warmth or swelling as normally examined and cared for during standard radiation therapy. If radiation burns are noted, the subject will be treated normally and depending on the severity of the radiation burns, may be removed from the study treatment and treated through standard of care.

NCT ID: NCT04110977 Recruiting - Clinical trials for Radiation Dermatitis

A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer

RAREST-02
Start date: October 10, 2020
Phase: N/A
Study type: Interventional

The goal of this randomized trial is to investigate whether the addition of a reminder app to standard care leads to a reduction of dermatitis and oral mucositis during radio(chemo)therapy for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). The primary endpoint is the rate of patients experiencing grade ≥2 radiation dermatitis at 60 Gy of radiotherapy. 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. If the addition of a reminder app to standard care will result in a significant reduction of radiation toxicity, it could become a helpful tool for these patients.

NCT ID: NCT04059809 Completed - Breast Cancer Clinical Trials

Photobiomodulation for Breast Cancer Radiodermatitis

Start date: September 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective single blind controlled randomized trial to evaluate the superiority of photobiomodulation (PBM) using LED-therapy in reducing the prevalence of radiodermatitis in breast cancer compared to usual local care.

NCT ID: NCT03988556 Completed - Clinical trials for Radiation Dermatitis

Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis

SafePBM
Start date: July 4, 2019
Phase: N/A
Study type: Interventional

The main objective of the present study is to investigate the feasibility, safety and tolerability of CareMin650 in patients with 1) head & neck cancer at high risk of or suffering from oral mucositis and/or radiation dermatitis due to the administration of radiotherapy with or without chemotherapy with or without targeted therapy, 2) breast cancer at high risk of or suffering from radiation dermatitis due to the administration of radiotherapy.

NCT ID: NCT03941665 Completed - Clinical trials for Radiation Dermatitis

Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients

Start date: March 25, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effect of Gelronate gel, NaHA based product (medical device for topical application) vs. Aloevera gel, in prevention or minimizing of radiation induced skin reaction in breast cancer patients

NCT ID: NCT03910595 Completed - Breast Cancer Clinical Trials

Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients

Start date: March 14, 2019
Phase: N/A
Study type: Interventional

In patients undergoing adjuvant radiotherapy for breast cancer, radiation-induced skin toxicities are a common occurrence and adversely impact patients' quality of life (QOL). In the last decade, there have been no significant advances in preventing or treating radiation-induced skin toxicities. Recently, a phase III randomized trial by Herst et al. (n=78) in New Zealand showed that the prophylactic use of Mepitel Film reduced skin reaction severity by 92% compared to skin treated only with aqueous cream. Mepitel film has not been widely adopted in North America. To validate the efficacy of the film and guide the development of a larger multi-centre phase II study, a pilot study testing the efficacy of the film is proposed. In the study, 30 patients will have the film applied on their breast for the duration of radiation treatment and their skin reactions will be assessed throughout the treatment and after the treatment. The investigators hypothesize that the severity and incidence rates of skin reactions for patients using Mepitel film will be lower when compared to real world data from our centre, and that cosmetic outcomes will be improved with the film.

NCT ID: NCT03883828 Completed - Clinical trials for Radiation Dermatitis

Bacterial Decolonization to Prevent Radiation Dermatitis

Start date: June 3, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.

NCT ID: NCT03716583 Completed - Breast Cancer Clinical Trials

Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer

MELADERM
Start date: April 30, 2019
Phase: Phase 2
Study type: Interventional

The aim of the present randomized double-blinded placebo-controlled clinical trial is to investigate if melatonin can protect against acute radiation dermatitis in patients with early breast cancer receiving radiation therapy, and whether this has an impact on the patients' quality of life.

NCT ID: NCT03559218 Completed - Clinical trials for Radiation Dermatitis

KeraStat(R) Cream for Radiation Dermatitis

Start date: April 11, 2018
Phase: N/A
Study type: Interventional

The primary objectives of the proposed research are to evaluate patient use of KeraStat Cream and collect data to inform a larger future trial.

NCT ID: NCT03546803 Completed - Clinical trials for Radiation Dermatitis

3M Cavilon Advanced Skin Protectant for the Prophylaxis of Radiation Dermatitis

Start date: February 19, 2018
Phase:
Study type: Observational

This study observes a liquid skin protectant that is a polymeric-cyanoacrylate solution designed to protect intact or damaged skin due to radiation.